Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial

Summary: Background: Intranasal vaccination may induce protective local and systemic immune responses against respiratory pathogens. A number of intranasal SARS-CoV-2 vaccine candidates have achieved protection in pre-clinical challenge models, including ChAdOx1 nCoV-19 (AZD1222, University of Oxfo...

Full description

Bibliographic Details
Main Authors: Meera Madhavan, Adam J. Ritchie, Jeremy Aboagye, Daniel Jenkin, Samuel Provstgaad-Morys, Iona Tarbet, Danielle Woods, Sophie Davies, Megan Baker, Abigail Platt, Amy Flaxman, Holly Smith, Sandra Belij-Rammerstorfer, Deidre Wilkins, Elizabeth J. Kelly, Tonya Villafana, Justin A. Green, Ian Poulton, Teresa Lambe, Adrian V.S. Hill, Katie J. Ewer, Alexander D. Douglas
Format: Article
Language:English
Published: Elsevier 2022-11-01
Series:EBioMedicine
Subjects:
Adenovirus vector
Intranasal vaccination
SARS-CoV-2
Mucosal antibody
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396422004807

Internet

http://www.sciencedirect.com/science/article/pii/S2352396422004807

Similar Items